HIGHLIGHTS
SUMMARY
And Objective: Identifying patients that benefit from cisplatin-based adjuvant chemotherapy is a major issue in the management of muscle-invasive bladder cancer (MIBC). The aim of this study is to correlate "luminal" and "basal" type protein expression with histological subtypes, to investigate the prognostic impact on survival after adjuvant chemotherapy and to define molecular consensus subtypes of "double negative" patients (i.e., without expression of CK5/6 or GATA3). Double negative cases were classified as NE-like (30%), stromarich (30%), and Ba/Sq (40%) consensus molecular subtypes and displaying different histological subtypes. IHC . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.